Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women
AUTOR(ES)
Dawar, Meenakshi
RESUMO
COUNTRIES WITH A LOW RISK OF HEPATITIS B (HB) lack data on the effectiveness of universal HB vaccination programs for children. British Columbia began a program in 1992, offering HB vaccination to 11 year olds. We conducted an anonymous, unlinked serologic survey 7 years later, analyzing a random sample of specimens (n = 1215) from women aged 15–44 years who had undergone antenatal rubella testing. Among those aged 15–19 years inclusive there was no evidence of chronic HB (HB surface antigen), the proportion with evidence of acute HB (anti-HB core antibody) was only 0.6% (compared with 6.5% for the entire sample), and evidence of protective immunity was strong: the prevalence of anti-HB surface antibody (anti-HBs) was 79.1% (compared with 41.4% for the entire sample) and the geometric mean titre was 34.9 IU/mL (compared with 0.6–0.8 IU/mL for the older groups [p < 0.001]).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154915Documentos Relacionados
- Foundation calls for universal hepatitis B vaccination in UK infants
- Psychosocial impact of chronic infection with hepatitis B virus on British patients.
- Seroprevalence of hepatitis B markers among female and transsexual sex workers in Athens, Greece.
- British Columbia: Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia
- Seroprevalence of hepatitis B and C infection markers among children and adolescents in the southern Brazilian region